Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Gains from Sales and Divestitures (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Gains from Sales and Divestitures for 7 consecutive years, with $19505.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 12.64% to $19505.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $19505.0, a 12.64% decrease, with the full-year FY2025 number at $19505.0, down 12.64% from a year prior.
  • Gains from Sales and Divestitures was $19505.0 for Q4 2025 at Fulcrum Therapeutics, roughly flat from $19505.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $42858.0 in Q3 2021 to a low of $5496.0 in Q1 2023.
  • A 5-year average of $21125.4 and a median of $19505.0 in 2025 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: plummeted 89.7% in 2021, then soared 110.15% in 2024.
  • Fulcrum Therapeutics' Gains from Sales and Divestitures stood at $42858.0 in 2021, then tumbled by 76.26% to $10174.0 in 2022, then skyrocketed by 78.34% to $18144.0 in 2023, then rose by 23.05% to $22326.0 in 2024, then fell by 12.64% to $19505.0 in 2025.
  • Per Business Quant, the three most recent readings for FULC's Gains from Sales and Divestitures are $19505.0 (Q4 2025), $19505.0 (Q3 2025), and $19505.0 (Q2 2025).